BREAST CANCER

Patients with ER-positive breast cancer, which accounts for approximately 70% of all cases, have benefited from the use of hormonal therapies to treat their disease.

Although targeted antibodies in cancer have been promising, most have only marginal activity in their targeted cancer and must be paired with a chemotherapeutic agent to maximize efficacy.

Gene expression profiling via the Oncotype DX 21-gene recurrence score assay has been used to assess risk and predict recurrence in hundreds of thousands of women over the course of nearly a decade.

The development of new drug combinations to treat patients with ER-negative breast cancer is being advanced by a growing understanding of the protein kinase activity along the EGFR pathway.

Emanuel F. Petricoin III, PhD, Co-Director, Center for Applied Proteomics & Molecular Medicine, Professor of Life Sciences, George Mason University, discusses the use of the reverse phase protein microarray (RPPA).

Fabrice André, MD, PhD, has focused his research on translational oncology and the development of novel targeted agents for the treatment of breast cancer through his research as director of INSERM Unit U981 at the Institut Gustave-Roussy in Villejuif, France.

Patrick Borgen, MD, chair, Department of Surgery, director, Maimonides Breast Cancer Center, discusses the Miami Breast Cancer Conference.